Rule 52 of the Patents Rules, 2003
Omitted provision
Rule 52 was part of the Exclusive Marketing Rights procedure in the Patents Rules and was omitted when that whole scheme was repealed.
Official legal text
The number is still shown because Indian statutes are not renumbered when something is taken out. The provision is simply marked as omitted. Documents created before the change, including granted patents and decided cases, continue to cite it, so the reference has to remain understandable.
Treat this page as a guide. The provision as officially published, along with the Gazette notifications that apply to it, remains the governing text and overrides any simplification here.
What this rule requires, step by step
Chapter V of the Patents Rules, 2003 ran from Rule 49 to Rule 54 and gave working detail to the Exclusive Marketing Rights sections of the Act. Rule 52 was one of those six rules. During the transition years the Controller had to handle a small and unusual class of files: applications for medicines and agricultural chemicals that could not yet be granted, together with requests for a temporary right to market the product. Chapter V told the office and the applicant how those requests were to be dealt with on paper. It was a self-contained procedure, separate from the ordinary route that every other invention followed.
That separate track closed in 2005. Once the Patents (Amendment) Act, 2005 allowed product patents in these fields and deleted the Exclusive Marketing Rights sections, the pending stored applications were released into normal examination and the special procedure became pointless. Rule 52 was omitted along with the rest of Chapter V. For a modern reader the useful lesson is structural: rules in the Patents Rules exist to carry out sections of the Act, so when a section goes, its rules go too. If you meet a rule marked omitted, the first question is always which section it used to serve.
Why this rule matters
Anyone tracing the procedural history of a pre-2005 pharmaceutical or agrochemical application in India.
Only in historical or academic work; it never arises in a current filing or opposition.
Nothing. It imposes no duty and confers no right.
No risk in ignoring it; the risk lies in assuming a special route still exists for medicines.
How it works in practice
An examiner's file note from the transition years
A patent agent in Chennai is asked to advise on the validity of an old Indian patent covering a veterinary medicine. The file history shows the application was filed in 1997 but was not examined for several years, and there is correspondence referring to Chapter V of the Patents Rules. The agent explains the sequence to the client, Trichy Tool Works, which now wants to use the compound in a different formulation. Between 1995 and 2004 such applications were held without examination, and a separate temporary marketing right could be sought under the rules that once included Rule 52. From 2005 the held applications were taken up and examined like any other, which is why the file suddenly becomes active in that year. The agent points out that the old procedure has no bearing on validity today. What matters is whether the granted claims meet the tests of novelty, inventive step and section 3, and whether a revocation ground exists. The client asks for a full validity opinion on that basis.
Simplified illustration only. Actual legal outcomes depend on the facts.
Key points to remember
- Chapter V of the Patents Rules, 2003 contained a separate paper procedure for Exclusive Marketing Rights.
- Rule 52 was one of the six rules in that chapter and applied only to that special class of file.
- The procedure closed once product patents became available and the parent sections were deleted in 2005.
- A rule in the Patents Rules cannot survive the section of the Act it was made to carry out.
Connected provisions
The link between a rule and its section matters in practice, because an argument about whether a procedure is valid usually starts with the parent provision. The connected sections are listed here, apart from the explanation, so the chain of authority is easy to follow.
Forms, deadlines and fees
The official fee for anything described on this page is set out in the First Schedule to the Patents Rules. It is not the same for every applicant, and it is not the same for online and physical filing, which is why no amount is stated here. How Indian patent fees work.
Related judgments
Case summaries are published only after a qualified reviewer has checked the judgment, the citation and the way the holding is described. Nothing has cleared that review for this provision yet, so nothing is listed here. We would rather show no case note than one that misstates what a court decided. How case notes are prepared.
Questions people ask about Rule 52
Do medicines follow a different patent procedure in India today?
No. Medicines follow the same route as every other invention: filing, publication, request for examination, examination report, reply, possible opposition and then grant or refusal. What differs is the substantive test applied. Section 3(d) limits patents on new forms of known substances unless enhanced efficacy is shown, and section 3(e) limits mere admixtures. There are also special public interest tools such as compulsory licensing. But the procedural path is the ordinary one.
How can I tell which section an omitted rule used to serve?
Look at the chapter heading above the rule in the Patents Rules and at the rules on either side of it. Rules are grouped by subject, so a rule sitting under a chapter about Exclusive Marketing Rights served the corresponding sections of the Act. Older printed editions of the Rules, published before the amendment, carry the full text and show the link directly. Commentaries covering the 2005 amendments also map the deleted rules to the deleted sections.
Questions about an old Indian pharmaceutical patent?
MYCrave Consultancy reads file histories and explains what a granted claim really covers today.
You will be speaking with MYCrave Consultancy & Services, the firm that operates this platform. General questions are answered free; matter‑specific work is quoted before anything is done.